Six researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, have been named in a list of the world's most influential and innovative researchers over the last decade.

Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.

The Royal Marsden NHS Foundation Trust will establish a state-of-the-art liquid biopsy testing facility for cancer clinical diagnostics and research following a partnership with Guardant Health, a leading precision oncology company.

Dr Richard Lee, Consultant Respiratory Physician and Champion for Early Cancer Diagnosis at The Royal Marsden NHS Foundation Trust, has been appointed as the NIHR's national cancer lead for screening, prevention and early detection. Dr Lee will combine his lead NIHR role for screening, prevention and early detection of cancer and non-cancerous conditions with his existing responsibilities.

Researchers at The Royal Marsden, Francis Crick Institute and University College London (UCL) have found immune cell patterns within tumours that can help predict whether patients with kidney cancer will respond to immunotherapy.

Results from the ADAPTeR clinical trial were published in Cancer Cell journal on Thursday 28 October.

A third dose of the COVID-19 vaccine could increase protection from COVID-19 for people with cancer, and especially blood cancer, according to a new study from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust published today in Nature Cancer (Wednesday 27 October).

Earlier this year, BRC Clinical Research Fellows Susanna Slater and Justin Mencel attended the 12th annual NIHR Infrastructure Doctoral Research Training Camp hosted by the NIHR Academy.

Men who inherit an increased risk of cancer through ‘Lynch syndrome’ could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.

Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.